Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for Depression in Breast Cancer
NCT02637466Phase 4Withdrawn
- Sponsor
- University of Miami
- Start
- Jul 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Vortioxetine with Placebo (2 arms). Primary endpoint: Hamilton Depression Rating Scale-21 at 16 weeks. Planned start Jul 2016; status: withdrawn.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02637466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637466.